Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

NCT02962804 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Due to competing trials. Stopped before IRB approval.

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Nivolumab
RADIATION: Radiation

Sponsor

University of Kansas Medical Center